Literature DB >> 18248786

Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN.

Xiaoxia Sun1, Jian Zhang, Lihua Wang, Zhigang Tian.   

Abstract

More and more studies show that signal transducer and activator of transcription 3 (STAT3) is frequently constitutively activated in a wide number of malignancies and named as an attractive molecular target for tumor treatment. Here, we employed STAT3-decoy ODN, which specifically block over-activated STAT3, to treat human hepatocellular carcinoma (HCC) cells, and evaluated the cellular proliferation ability and investigated the molecular mechanisms in vitro. The results demonstrated that the proliferation of HCC cells was suppressed significantly by STAT3-decoy ODN, being associated with the increased apoptosis and cell arrest at G0/G1 to S phase transition. Further investigates showed the expression of STAT3-regulated genes including bcl-x1, cyclin D1 and c-myc, which involved in cell apoptosis and cell cycle progression, were down-regulated significantly both at transcription and translation levels. These data suggested that STAT3 may be potentially used as a molecular target in HCC therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248786     DOI: 10.1016/j.canlet.2007.12.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  31 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

Review 2.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

3.  Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Authors:  Malabika Sen; Sonali Joyce; Mary Panahandeh; Changyou Li; Sufi M Thomas; Jessica Maxwell; Lin Wang; William E Gooding; Daniel E Johnson; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

4.  Silencing SOCS3 could inhibit TNF-α induced apoptosis in 3T3-L1 and mouse preadipocytes.

Authors:  Xia Zhao; Renli Qi; Chao Sun; Yunfei Xie
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

Review 5.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

6.  S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling.

Authors:  Yi Xie; Sutapa Kole; Patricia Precht; Michael J Pazin; Michel Bernier
Journal:  Endocrinology       Date:  2008-11-06       Impact factor: 4.736

Review 7.  The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.

Authors:  Jessica L Geiger; Jennifer R Grandis; Julie E Bauman
Journal:  Oral Oncol       Date:  2015-12-28       Impact factor: 5.337

8.  Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.

Authors:  Xiao Cui; Zhi-Ping Hu; Zhao Li; Peng-Ji Gao; Ji-Ye Zhu
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 9.  Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.

Authors:  Francis Leblanc; Dan Zhang; Xin Liu; Thomas P Loughran
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

Review 10.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.